18:21 , May 25, 2018 |  BC Week In Review  |  Company News

Antengene adds bundle of Karyopharm assets to pipeline

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
22:16 , May 24, 2018 |  BC Extra  |  Company News

Antengene fills pipeline with Karyopharm deal

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) granted cancer company Antengene Corp. (Shanghai, China) exclusive Asian rights to four compounds, significantly building out the Chinese company's clinical pipeline. Antengene will develop and commercialize Karyopharm's selinexor (KPT-330) and eltanexor...
23:14 , Mar 20, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Cellular assays CRISPR-based screening in human cells could help identify the therapeutic targets of small molecules. The method involved three steps: generating in-frame mutations in human cell lines by engineering them to express CRISPR-associated...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
18:58 , Sep 20, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer In vitro, cell-based and mouse studies identified an aminoanilide-based dual NamPRT / HDAC1 inhibitor that could help treat colorectal cancer. Chemical synthesis and in vitro testing of ortho -aminoanilide analogs in enzymatic...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

KPT-9274: Phase I started

Karyopharm began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate oral KPT-9274 with or without extended-release niacin given 3 times a week every other day of a 28-day cycle in about 175 patients....
07:00 , Oct 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Nicotinamide phosphoribosyltransferase (NamPRT; NAMPT) In vitro and mouse studies have identified a series of aminopropyl carbazole-based NAMPT inhibitors that could help treat traumatic brain...
07:00 , Oct 2, 2014 |  BC Innovations  |  Cover Story

NAMPT neuroprotection

Google Inc .-backed antiaging play Calico LLC has in-licensed its first molecules-inhibitors of neurodegeneration-following findings from The University of Texas Southwestern Medical Center and The University of Iowa that the compounds protect mice from traumatic...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

2M BioTech, Calico deal

2M BioTech granted Calico exclusive, worldwide rights to develop and commercialize a portfolio of modulators of nicotinamide phosphoribosyl transferase ( NamPRT ; NAMPT ). The deal includes 2M's preclinical P7C3 program, which has been focused...
02:40 , Sep 12, 2014 |  BC Extra  |  Company News

Calico gains P7C3 neurodegeneration program

2M BioTech L.P. (Dallas, Texas) granted Calico LLC (South San Francisco, Calif.) exclusive, worldwide rights to develop and commercialize a portfolio of modulators of nicotinamide phosphoribosyl transferase ( NamPRT ; NAMPT ). The deal includes...